Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | NTRK1 fusion |
Gene Variant Detail | |
Relevant Treatment Approaches | Trk Receptor Inhibitor (Pan) |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02465060 | Phase II | Erdafitinib Trametinib Crizotinib Sapanisertib Fexagratinib Dasatinib Osimertinib Palbociclib Capivasertib Larotrectinib Ulixertinib Nivolumab + Relatlimab Copanlisib Sunitinib Nivolumab Pertuzumab + Trastuzumab Ipatasertib Dabrafenib + Trametinib Binimetinib Adavosertib Afatinib Defactinib GSK2636771 Vismodegib Ado-trastuzumab emtansine Taselisib | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | Active, not recruiting | USA | 2 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02637687 | Phase I | Larotrectinib | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children (SCOUT) | Active, not recruiting | USA | TUR | SWE | POL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | AUS | 4 |
NCT02650401 | Phase I | Entrectinib | Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG) | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | 2 |
NCT03155620 | Phase II | Tazemetostat Tipifarnib Larotrectinib LY3023414 Vemurafenib Selpercatinib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Active, not recruiting | USA | CAN | AUS | 1 |
NCT03213704 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03520686 | Phase III | Carboplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nogapendekin alfa inbakicept + Pembrolizumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Nab-paclitaxel + Pembrolizumab Nogapendekin alfa inbakicept + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nab-paclitaxel + Nogapendekin alfa inbakicept + Pembrolizumab | QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC. | Active, not recruiting | USA | 0 |
NCT03834961 | Phase II | Larotrectinib | Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia | Active, not recruiting | USA | CAN | 0 |
NCT04083976 | Phase II | Erdafitinib | A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR) | Active, not recruiting | USA | POL | ITA | GBR | FRA | ESP | DEU | BRA | BEL | AUS | ARG | 4 |
NCT04211337 | Phase III | Vandetanib Cabozantinib Selpercatinib | A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531) | Active, not recruiting | USA | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | 5 |
NCT04484142 | Phase II | Datopotamab deruxtecan | Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) | Active, not recruiting | USA | NLD | ITA | HUN | FRA | ESP | DEU | 3 |
NCT04526691 | Phase I | Cisplatin + Datopotamab deruxtecan + Pembrolizumab Carboplatin + Datopotamab deruxtecan + Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | Active, not recruiting | USA | ITA | ESP | 2 |
NCT05117242 | Phase II | Acasunlimab + Pembrolizumab Acasunlimab | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer | Active, not recruiting | USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | 1 |
NCT05200481 | Phase II | Brigatinib + Carboplatin + Pemetrexed Disodium Brigatinib | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) (MP-ALK) | Active, not recruiting | FRA | 0 |
NCT05781308 | Phase II | Atezolizumab + Bevacizumab + Paclitaxel Bevacizumab + Paclitaxel | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy (ADAPTABLE) | Active, not recruiting | FRA | 0 |
NCT06532032 | Phase Ib/II | Amivantamab-vmjw + Docetaxel | A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer (swalloWTail) | Active, not recruiting | USA | TUR | GBR | 1 |
NCT02097810 | Phase I | Entrectinib | Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations. (STARTRK-1) | Completed | USA | 1 |
NCT02122913 | Phase I | Larotrectinib | A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer | Completed | USA | 0 |
NCT03215511 | Phase Ib/II | Selitrectinib | A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer | Completed | USA | ITA | IRL | FRA | ESP | DNK | DEU | BEL | AUS | 1 |
NCT03639714 | Phase Ib/II | GRT-C901 + GRT-R902 + Ipilimumab + Nivolumab | A Study of a Personalized Neoantigen Cancer Vaccine | Completed | USA | AUS | 0 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Completed | USA | 0 |
NCT03066661 | Expanded access | Entrectinib | Expanded Access to Entrectinib for Cancers With NTRK1/2/3, ROS1, or ALK Gene Fusions | No longer available | USA | 0 |
NCT05597800 | Phase II | Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Cisplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Ipilimumab + Nivolumab + Paclitaxel | Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome (LUNGVIR) | Not yet recruiting | ITA | 0 |
NCT06364917 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Pembrolizumab + Pemetrexed Disodium Ipilimumab + Nivolumab Carboplatin + Ipilimumab + Nivolumab + Paclitaxel Carboplatin + Ipilimumab + Nivolumab + Pemetrexed Disodium Carboplatin + Paclitaxel + Pembrolizumab | DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | Not yet recruiting | USA | 0 |
NCT07020065 | Phase II | Carboplatin + Cemiplimab + Gemcitabine Carboplatin + Cemiplimab + Pemetrexed Disodium Cemiplimab Carboplatin + Cemiplimab + Paclitaxel | Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | Not yet recruiting | CHE | 0 |
NCT01639508 | Phase II | Cabozantinib | Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity | Recruiting | USA | 0 |
NCT03556228 | Phase I | VMD-928 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Recruiting | USA | 1 |
NCT03994796 | Phase II | Adagrasib Abemaciclib GDC-0084 Entrectinib | Genetic Testing in Guiding Treatment for Patients With Brain Metastases | Recruiting | USA | 0 |
NCT04085315 | Phase I | Alisertib + Osimertinib | Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Recruiting | USA | 0 |
NCT04094610 | Phase Ib/II | Repotrectinib | A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CAN | AUS | 3 |
NCT04116541 | Phase II | Alectinib Regorafenib Dabrafenib + Trametinib Cabozantinib Avapritinib | A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. (MegaMOST) | Recruiting | FRA | 0 |
NCT04270591 | Phase Ib/II | SCC244 | Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer | Recruiting | USA | 2 |
NCT04302025 | Phase II | Entrectinib Atezolizumab Divarasib Alectinib | A Study of Multiple Therapies in Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04467801 | Phase II | Ipatasertib Docetaxel + Ipatasertib | Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy (Ipat-Lung) | Recruiting | USA | 0 |
NCT04589845 | Phase II | Alectinib Divarasib Entrectinib RP-3500 | Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Recruiting | USA | POL | NZL | ITA | ISR | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | BEL | AUS | 9 |
NCT04655404 | Phase I | Larotrectinib | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion | Recruiting | USA | DEU | CAN | AUS | 0 |
NCT04923126 | Phase Ib/II | Mirdametinib | SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma | Recruiting | USA | 0 |
NCT05064280 | Phase II | Lenvatinib + Pembrolizumab | Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases | Recruiting | USA | 0 |
NCT05077800 | Phase II | Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Elraglusib + Fluorouracil + Irinotecan + Leucovorin + Losartan + Oxaliplatin | FOLFIRINOX + 9-Ing-41 + Losartan In Pancreatic Cancer | Recruiting | USA | 0 |
NCT05159245 | Phase II | Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib | The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE) | Recruiting | FIN | 0 |
NCT05215340 | Phase III | Pembrolizumab Datopotamab deruxtecan + Pembrolizumab | Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (TROPION-Lung08) | Recruiting | USA | TUR | ROU | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 9 |
NCT05541822 | Phase II | ABN401 + Lazertinib ABN401 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Recruiting | USA | 2 |
NCT05589818 | Phase II | Pembrolizumab | Pembrolizumab for Advanced NSCLC and PS 2-3 | Recruiting | USA | 0 |
NCT05671510 | Phase III | ONC-392 Docetaxel | ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) | Recruiting | USA | TUR | NLD | ITA | GBR | ESP | DEU | CAN | BEL | AUS | 2 |
NCT05676749 | Phase I | Aldesleukin + C-TIL051 + Pembrolizumab | C-TIL051 in Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT05783323 | Phase II | Larotrectinib | Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT05785754 | Phase I | Doxorubicin + Tebentafusp DCSZ11 + Pembrolizumab DCSZ11 | DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Recruiting | USA | AUS | 2 |
NCT06074588 | Phase III | Docetaxel SKB264 Pemetrexed Disodium | Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Recruiting | USA | TUR | POL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | AUS | 11 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | NOR | NLD | ITA | GBR | FRA | ESP | CAN | BEL | AUS | 3 |
NCT06495125 | Phase II | Defactinib + Nivolumab + RO5126766 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT06528691 | Phase II | Entrectinib Carboplatin + Cyclophosphamide + Etoposide + Filgrastim Carboplatin + Cyclophosphamide + Etoposide + Pegfilgrastim | Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | Recruiting | USA | 0 |
NCT06561386 | Phase III | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Nivolumab + Pemetrexed Disodium + Relatlimab Cisplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Nivolumab + Pemetrexed Disodium + Relatlimab | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 1-49% (RELATIVITY1093) | Recruiting | USA | TUR | ROU | POL | NZL | NLD | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CHE | BRA | BEL | AUT | AUS | ARG | 11 |
NCT06625775 | Phase I | BBO-10203 + Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin BBO-10203 + Trastuzumab BBO-10203 + Fulvestrant + Ribociclib BBO-10203 | Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06644768 | Phase Ib/II | Pembrolizumab DS-3201b + Pembrolizumab | A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Recruiting | USA | BRA | ARG | 3 |
NCT06758401 | Phase III | Pembrolizumab Pembrolizumab + SGN-B6A | This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. (Be6A Lung-02) | Recruiting | USA | POL | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BGR | BEL | 3 |
NCT06946797 | Phase II | Paclitaxel Cisplatin Pemetrexed Disodium Carboplatin Ipilimumab + Nivolumab | A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate-1533) | Recruiting | USA | TUR | ROU | POL | ITA | GRC | FRA | BRA | 3 |
NCT07017829 | Phase II | GT103 + Pembrolizumab | GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer | Recruiting | USA | 0 |
NCT01804530 | Phase I | PLX7486 Gemcitabine + Nab-paclitaxel | Phase 1 Study of PLX7486 as Single Agent and With Gemcitabine Plus Nab-Paclitaxel in Patients With Advanced Solid Tumors | Terminated | USA | 0 |
NCT02587650 | Phase II | Ceritinib Capmatinib Regorafenib Entrectinib | Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma | Terminated | USA | 0 |
NCT03827850 | Phase II | Erdafitinib | FGFR Inhibitor in FGFR Dysregulated Cancer (FIND) | Terminated | DEU | 0 |
NCT04265534 | Phase II | Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium + Telaglenastat Carboplatin + Dexamethasone + Pembrolizumab + Pemetrexed Disodium | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC (KEAPSAKE) | Terminated | USA | 0 |
NCT04581824 | Phase II | Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Dostarlimab-gxly + Pemetrexed Disodium Carboplatin + Dostarlimab-gxly + Pemetrexed Disodium | Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | ROU | POL | ITA | FRA | ESP | DEU | BRA | ARG | 3 |
NCT04827576 | Phase II | Docetaxel + Hu5F9-G4 | Study of Magrolimab in Patients With Solid Tumors (ELEVATELung&UC) | Terminated | USA | POL | GBR | FRA | ESP | 0 |
NCT04862780 | Phase Ib/II | BLU-945 BLU-945 + Osimertinib | (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC | Terminated | USA | NLD | GBR | FRA | ESP | CAN | 4 |
NCT04901806 | Phase Ib/II | PBI-200 | Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors | Terminated | USA | ITA | GBR | FRA | ESP | DNK | DEU | AUS | 3 |
NCT05153408 | Phase Ib/II | BLU-701 BLU-701 + Osimertinib BLU-701 + Carboplatin + Pemetrexed Disodium | (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | Terminated | USA | 0 |
NCT05241873 | Phase Ib/II | BLU-451 | (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | Terminated | USA | CAN | 3 |
NCT05313009 | Phase Ib/II | Sotorasib + TH-4000 | Tarlox and Sotorasib in Patients With KRAS G12C Mutations | Terminated | USA | 0 |
NCT05435846 | Phase I | Capmatinib + Trametinib | Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | Terminated | USA | 0 |
NCT05469178 | Phase Ib/II | Bemcentinib + Carboplatin + Pembrolizumab + Pemetrexed Disodium | A Clinical Study of Bemcentinib with Standard of Care Chemoimmunotherapy in Untreated Advanced/metastatic Non-small Cell Lung Cancer Patients with a Mutation in the STK11 Gene | Terminated | USA | POL | ITA | HUN | GRC | FRA | ESP | 0 |
NCT06094296 | Phase II | Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Cisplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Pemetrexed Disodium BMS-986315 + Carboplatin + Nivolumab + Paclitaxel Carboplatin + Nivolumab + Pemetrexed Disodium Carboplatin + Nivolumab + Paclitaxel | A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | Terminated | USA | AUS | 0 |
NCT05935774 | Phase II | Atezolizumab + Trabedersen | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | Withdrawn | USA | 0 |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: